Associations between acute and chronic graft-versus-host disease

Author:

Tamaki Masaharu12ORCID,Akahoshi Yu13ORCID,Inamoto Yoshihiro4ORCID,Morita Kaoru5ORCID,Uchida Naoyuki6,Doki Noriko7ORCID,Tanaka Masatsugu8,Nishida Tetsuya9,Ohigashi Hiroyuki10,Nakamae Hirohisa11ORCID,Onizuka Makoto12,Katayama Yuta13ORCID,Matsuoka Ken-ichi14,Sawa Masashi15,Ishimaru Fumihiko16ORCID,Kanda Yoshinobu15,Fukuda Takahiro17,Atsuta Yoshiko1819ORCID,Terakura Seitaro20ORCID,Kanda Junya21ORCID

Affiliation:

1. 1Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan

2. 2Division of Emerging Medicine for Integrated Therapeutics, Center for Molecular Medicine, Jichi Medical University Shimotsuke, Japan

3. 3Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

4. 4Department of Bone and Marrow Transplantation & Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan

5. 5Division of Hematology, Jichi Medical University, Shimotsuke, Japan

6. 6Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan

7. 7Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

8. 8Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

9. 9Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan

10. 10Department of Hematology, Hokkaido University Hospital, Sapporo, Japan

11. 11Department of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan

12. 12Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan

13. 13Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan

14. 14Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

15. 15Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan

16. 16Technical Department, Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan

17. 17Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

18. 18Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan

19. 19Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan

20. 20Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

21. 21Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Abstract

Abstract Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.

Publisher

American Society of Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3